- Automated Chemical Synthesis Workshop
- Assay Guidance Workshop for High-Throughput Screening and Lead Discovery
- NCATS Data Translator Meeting
- Second Strategic Partnerships for Drug Repurposing Forum
Oct. 19―20, 2017
Day 1: 8:45 a.m. to 5:30 p.m. ET
Day 2: 8:30 a.m. to 4:00 p.m. ET
National Institutes of Health (Main Campus)
William H. Natcher Building
45 Center Drive, Room D
Bethesda, Maryland 20892
The NCATS Chemical Genomics Center (NCGC), formerly known as the NIH Chemical Genomics Center, was created in 2008 as a comprehensive screening center in the Molecular Libraries Probe Production Centers Network, part of the NIH Common Fund’s Molecular Libraries Program. The original goals of the NCGC were to translate the discoveries of the Human Genome Project into biology and disease insights and ultimately new therapeutics through small molecule assay development, high-throughput screening, informatics and chemistry. View the NCGC’s current goals.
NCATS is interested in expanding and evolving the NCGC to include automated chemical synthesis as a tool to discover unexplored, biologically relevant chemicals and facilitate drug discovery. This workshop is a landscaping exercise to identify challenges and research opportunities in automated chemical synthesis. More specifically, workshop organizers aim to determine where NCATS could play a catalytic role in advancing the field, to identify the type of investment NCATS should make and to engage and coordinate other stakeholders.
Oct. 23, 2017
8 a.m. to 6:30 p.m. ET
University of North Carolina at Chapel Hill
150 Stadium Drive
Chapel Hill, North Carolina 27514
NCATS is supporting this full-day workshop that will cover a broad range of critical concepts underlying assay development for high-throughput screening and lead discovery projects. This workshop, which will feature presentations by several NCATS staff members, is designed to disseminate critical information about the implementation of robust assay methods and is particularly relevant for researchers developing bioassays for the discovery of drugs or chemical probes. Many of the workshop instructors have 20 to 30 years of experience in the field of drug discovery.
Along with the Assay Guidance Manual, this workshop will be a valuable resource for academic, industrial and government laboratory scientists who are developing test methods for low- or high-throughput screening that are amenable to automation using appropriate statistical and operational concepts. It will also be beneficial to early career researchers and experienced investigators who wish to learn about the latest assay concepts for high-throughput screening and lead optimization.
Registration is $185. Be sure to register no later than Oct. 13, 2017.
Oct. 25, 2017
8:30 a.m. to 2:30 p.m. EDT
Renaissance Computing Institute
100 Europa Drive, Suite 540
Chapel Hill, NC 27517
NCATS launched the Biomedical Data Translator (Translator) program to accelerate biomedical translation for the research community. Through this program, NCATS will integrate existing biomedical data to help reveal new relationships within those data and identify novel opportunities for research. The initial focus of the program is to conduct data assessment and technical feasibility analyses for building a data "Translator" that integrates data sources and types ranging from patient level phenotypic data to molecular data relevant to understanding pathophysiology.
The feasibility assessment awardees began work in November 2016. By January 2017, the five teams comprised of 30 investigators from 11 institutions agreed to move forward to explore the potential of using a blackboard architecture as the framework for constructing a biomedical data translator. To pressure test various aspects of feasibility, cross-cutting research questions that have been difficult to address by other means will be addressed in demonstration projects to evaluate the functionality of the newly integrated data. The type of functionality explored includes:
- Examining the impact of environmental exposures on the onset or worsening of disease;
- Evaluating the ability to help patients for whom existing approaches have failed to identify the origin of their symptoms; and
- Better understanding relationships between rare and common diseases.
At this meeting, participants will learn about the progress made by the teams.
Contact Dena Procaccini for logistical questions.
Oct. 26―27, 2017
Hyatt Regency Boston Harbor
101 Harborside Drive
Boston, Massachusetts 02128
On Oct. 26, 2017, NCATS Program Officer Bobbie Ann Austin, Ph.D., who oversees NCATS’ Drug Development Partnership programs, will participate in two panel sessions at the 2nd Strategic Partnerships for Drug Repurposing Forum. The first panel focuses on partnerships with sponsors, patient advocacy groups and government to facilitate drug development research. The second panel explores two case studies on computational strategies for drug repurposing.
Additional featured speakers will address the latest indications for repurposing, rescuing and repositioning existing drugs to explore the newest innovations. Attendees will learn about the different resources available to them, including public-private partnerships, foundations, patient advocacy groups, universities and other funding partners.
Forum attendees will:
- Engage in case studies and panel discussions on how to excel in searching for drug repurposing opportunities and uncover new indications for existing drugs;
- Cover new methods in the pipeline by using innovative strategies to discover new therapeutic uses for existing molecules;
- Identify new technologies used for the evaluation of repurposed drugs;
- Explore how to develop strategic partnerships between the government, universities, patient advocacy groups, foundations and sponsors; and
- Learn about the Food and Drug Administration regulations (505b) for new drug applications and the intellectual property laws surrounding drug repurposing.
Nov. 6―7, 2017
9:15 a.m. to 5:15 p.m.
Hilton Washington DC / Rockville Hotel & Executive Meeting Center
1750 Rockville Pike
Rockville, Maryland 20852
Since 2013, the NIH Extracellular RNA Communication Consortium (ERCC) has been working to understand the biological functions of extracellular RNAs (exRNAs) and vesicles in the healthy body and in disease. The consortium aims to identify disease biomarkers that can be assayed from biofluids rather than through an invasive biopsy and to develop therapies for disease using exRNA and extracellular vesicles.
On Nov. 6―7, 2017, the ERCC will hold its semi-annual meeting that will showcase the latest developments in the field of exRNA and extracellular vesicle research. This meeting is sponsored by the NIH Common Fund’s ExRNA Communication program, which is led by a trans-NIH team including NCATS.
Be sure to register by Oct. 18, 2017.